RxDoctor Payments Data

Brenda Heim, PA

Medical · Williamsville, NYNPI 1699088773

Payments from drug & device makers

$4,822in general payments, 2019–2025

Across 252 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$557
  • AstraZeneca$530
  • Novo Nordisk$512
  • Pfizer$300
  • AbbVie$241
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,822100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,822 in reported general payments places this provider in the 85th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$22,502
Medicare patients
168
Services billed
388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin93$112,106
EliquisApixaban60$68,371
OzempicSemaglutide56$64,487
MounjaroTirzepatide44$46,954
XareltoRivaroxaban28$26,517
TrulicityDulaglutide14$21,168
JanuviaSitagliptin Phosphate17$19,288
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$9,806
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,307
FarxigaDapagliflozin Propanediol12$7,536
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$7,401
Metoprolol Succinate342$6,810
Levothyroxine Sodium412$5,783
Atorvastatin Calcium357$5,049
SynthroidLevothyroxine Sodium66$4,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$557$112,10693 claims
PfizerEliquis$300$68,37160 claims
Lilly USA, LLCMounjaro, Trulicity$1,009$68,12258 claims
Novo NordiskOzempic$512$64,48756 claims
Johnson & JohnsonXarelto$64$26,51728 claims
MerckJanuvia$40$19,28817 claims
AstraZenecaFarxiga, Symbicort$530$10,30924 claims
GSKTrelegy Ellipta$174$8,30713 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$5,783412 claims
AbbVieSynthroid$241$4,75866 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,395 medical providers in New York.

Other medical in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →